Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.

4 brokerages have issued 12-month price objectives for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $24.00 to $27.00. On average, they expect the company's stock price to reach $24.75 in the next twelve months. This suggests a possible upside of 102.0% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.

Catalyst Pharmaceuticals' stock was trading at $18.60 at the beginning of 2023. Since then, CPRX shares have decreased by 34.1% and is now trading at $12.25.
View the best growth stocks for 2023 here.

Catalyst Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 7,160,000 shares, an increase of 6.1% from the August 15th total of 6,750,000 shares. Based on an average daily trading volume, of 1,510,000 shares, the days-to-cover ratio is currently 4.7 days. Approximately 7.2% of the shares of the company are short sold.
View Catalyst Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CPRX earnings forecast.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.08. The biopharmaceutical company earned $99.58 million during the quarter, compared to analyst estimates of $92.77 million. Catalyst Pharmaceuticals had a net margin of 38.14% and a trailing twelve-month return on equity of 36.13%.

ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and ALPS Medical Breakthroughs ETF (SBIO).

Catalyst Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $380.00 million-$390.00 million, compared to the consensus revenue estimate of $380.21 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.88%), State Street Corp (8.87%), Dimensional Fund Advisors LP (2.32%), Geode Capital Management LLC (1.81%), Northern Trust Corp (1.32%) and Goldman Sachs Group Inc. (1.17%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CPRX stock can currently be purchased for approximately $12.25.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.31 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $1.01 on an earnings per share basis.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.